✦ LIBER ✦

Prevalence of Osteoporosis by Educational Level in a Cohort of Postmenopausal Women

✍ Scribed by M. Varenna; L. Binelli; F. Zucchi; D. Ghiringhelli; M. Gallazzi; L. Sinigaglia

Publisher: Springer-Verlag
Year: 1999
Tongue: English
Weight: 47 KB
Volume: 9
Category: Article
ISSN: 0937-941X
DOI: 10.1007/s001980050143

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Educational level and osteoporosis risk

Educational level and osteoporosis risk in postmenopausal Moroccan women: a classification tree analysis

✍ Fadoua Allali; Samira Rostom; Loubna Bennani; Redouane Abouqal; Najia Hajjaj-Has 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 140 KB

Longitudinal progression of fracture pre

Longitudinal progression of fracture prevalence through a population of postmenopausal women with osteoporosis

✍ Robert Lindsay; Simon Pack; Zhengqing Li 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 318 KB

Prevention of vertebral fractures by str

Prevention of vertebral fractures by strontium ranelate in postmenopausal women with osteoporosis

✍ Juliet Compston 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 155 KB

Vitamin D status in a large cohort of ea

Vitamin D status in a large cohort of early postmenopausal French women

✍ C. Ribot; J. M. Pouilles; F. Trémollieres 📂 Article 📅 1996 🏛 Springer-Verlag 🌐 English ⚖ 116 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

Seven Years of Treatment with Risedronat

Seven Years of Treatment with Risedronate in Women with Postmenopausal Osteoporosis

✍ D. D. Mellström; O. H. Sörensen; S. Goemaere; C. Roux; T. D. Johnson; A. A. Chin 📂 Article 📅 2004 🏛 Springer 🌐 English ⚖ 186 KB

The effects of 7 years of risedronate treatment were evaluated in a second 2-year extension of a 3-year vertebral fracture study in women with osteoporosis. For the first 5 years of the study, women received risedronate 5 mg/day or placebo according to the original randomization, with maintenance of